# Basiliximab Maintenance in Ulcerative Colitis

> **NCT01061996** · PHASE2 · TERMINATED · sponsor: **Cerimon Pharmaceuticals** · enrollment: 88 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Basiliximab

## Key facts

- **NCT ID:** NCT01061996
- **Lead sponsor:** Cerimon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 88 (ACTUAL)
- **Why stopped:** lack of efficacy
- **Last updated:** 2010-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01061996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01061996, "Basiliximab Maintenance in Ulcerative Colitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01061996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*